

Anna-Karin Olsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4999632/publications.pdf>

Version: 2024-02-01

36
papers

4,396
citations

394286

19
h-index

330025

37
g-index

39
all docs

39
docs citations

39
times ranked

8241
citing authors

#	ARTICLE	IF	CITATIONS
1	Extended cleavage specificity of a Chinese alligator granzyme B homologue, a strict Glu-ase in contrast to the mammalian Asp-ases. <i>Developmental and Comparative Immunology</i> , 2022, 128, 104324.	1.0	6
2	Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2029-2040.	2.0	13
3	Chicken cathepsin G-like - A highly specific serine protease with a peculiar tryptase specificity expressed by chicken thrombocytes. <i>Developmental and Comparative Immunology</i> , 2022, 129, 104337.	1.0	2
4	Quantitative In-Depth Transcriptome Analysis Implicates Peritoneal Macrophages as Important Players in the Complement and Coagulation Systems. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1185.	1.8	7
5	Inflammation and neutrophil extracellular traps in cerebral cavernous malformation. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 206.	2.4	12
6	Mast Cell Tryptase Potentiates Neutrophil Extracellular Trap Formation. <i>Journal of Innate Immunity</i> , 2022, 14, 433-446.	1.8	6
7	Platelet-Derived PDGFB Promotes Recruitment of Cancer-Associated Fibroblasts, Deposition of Extracellular Matrix and Tgfi ² Signaling in the Tumor Microenvironment. <i>Cancers</i> , 2022, 14, 1947.	1.7	10
8	Specific targeting of PDGFR ^Î 2 in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression. <i>Theranostics</i> , 2020, 10, 1122-1135.	4.6	35
9	Platelet-Specific PDGFB Ablation Impairs Tumor Vessel Integrity and Promotes Metastasis. <i>Cancer Research</i> , 2020, 80, 3345-3358.	0.4	47
10	TANK-binding kinase 1 is a mediator of platelet-induced EMT in mammary carcinoma cells. <i>FASEB Journal</i> , 2019, 33, 7822-7832.	0.2	23
11	Platelets, NETs and cancer. <i>Thrombosis Research</i> , 2018, 164, S148-S152.	0.8	83
12	Consensus guidelines for the use and interpretation of angiogenesis assays. <i>Angiogenesis</i> , 2018, 21, 425-532.	3.7	429
13	Trametinib prevents mesothelial-mesenchymal transition and ameliorates abdominal adhesion formation. <i>Journal of Surgical Research</i> , 2018, 227, 198-210.	0.8	14
14	Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice. <i>Oncolmmunology</i> , 2017, 6, e1320009.	2.1	51
15	Development of a novel therapeutic vaccine carrier that sustains high antibody titers against several targets simultaneously. <i>FASEB Journal</i> , 2017, 31, 1204-1214.	0.2	11
16	NETosis in Cancer - Platelet-Neutrophil Crosstalk Promotes Tumor-Associated Pathology. <i>Frontiers in Immunology</i> , 2016, 7, 373.	2.2	76
17	Tumor-Induced NETosis as a Risk Factor for Metastasis and Organ Failure. <i>Cancer Research</i> , 2016, 76, 4311-4315.	0.4	102
18	Immunity Gone Astray - NETs in Cancer. <i>Trends in Cancer</i> , 2016, 2, 633-634.	3.8	18

#	ARTICLE	IF	CITATIONS
19	Ras and TGF- β signaling enhance cancer progression by promoting the β -catenin transcriptional program. <i>Science Signaling</i> , 2016, 9, ra84.	1.6	33
20	Tumor-induced neutrophil extracellular traps are drivers of systemic inflammation and vascular dysfunction. <i>OncImmunology</i> , 2016, 5, e1098803.	2.1	5
21	Targeting Serglycin Prevents Metastasis in Murine Mammary Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0156151.	1.1	19
22	Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. <i>Science Signaling</i> , 2015, 8, ra125.	1.6	52
23	Vaccination approach to anti-angiogenic treatment of cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 155-171.	3.3	22
24	Neutrophil Extracellular Traps Accumulate in Peripheral Blood Vessels and Compromise Organ Function in Tumor-Bearing Animals. <i>Cancer Research</i> , 2015, 75, 2653-2662.	0.4	180
25	CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3794-3805.	3.2	190
26	Vaccines targeting self-antigens: mechanisms and efficacy-determining parameters. <i>FASEB Journal</i> , 2015, 29, 3253-3262.	0.2	25
27	NETosis in cancer. <i>Oncoscience</i> , 2015, 2, 900-901.	0.9	13
28	Therapeutic vaccination targeting the tumour vasculature. <i>Biochemical Society Transactions</i> , 2014, 42, 1653-1657.	1.6	4
29	Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer. <i>Oncotarget</i> , 2014, 5, 12418-12427.	0.8	52
30	HRG regulates tumor progression, epithelial to mesenchymal transition and metastasis via platelet-induced signaling in the pre-tumorigenic microenvironment. <i>Angiogenesis</i> , 2013, 16, 889-902.	3.7	19
31	The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-A as a prerequisite for clinical development. <i>Vaccine</i> , 2012, 30, 225-230.	1.7	20
32	Enhanced Platelet Activation Mediates the Accelerated Angiogenic Switch in Mice Lacking Histidine-Rich Glycoprotein. <i>PLoS ONE</i> , 2011, 6, e14526.	1.1	16
33	Vaccination against the extra domain B of fibronectin as a novel tumor therapy. <i>FASEB Journal</i> , 2010, 24, 4535-4544.	0.2	47
34	Activated Platelets Provide a Functional Microenvironment for the Antiangiogenic Fragment of Histidine-Rich Glycoprotein. <i>Molecular Cancer Research</i> , 2009, 7, 1792-1802.	1.5	36
35	Identification of potent biodegradable adjuvants that efficiently break self-tolerance: A key issue in the development of therapeutic vaccines. <i>Vaccine</i> , 2009, 28, 48-52.	1.7	16
36	VEGF receptor signalling in control of vascular function. <i>Nature Reviews Molecular Cell Biology</i> , 2006, 7, 359-371.	16.1	2,698